rs9282858
| Orientation | minus |
| Stabilized | minus |
| Geno | Mag | Summary |
|---|---|---|
| (G;G) | 0 | common in clinvar |
| Make rs9282858(A;A) |
| Make rs9282858(A;G) |
| Reference | GRCh38 38.1/142 |
| Chromosome | 2 |
| Position | 31580756 |
| Gene | SRD5A2 |
| is a | snp |
| is | mentioned by |
| dbSNP | rs9282858 |
| dbSNP (classic) | rs9282858 |
| ClinGen | rs9282858 |
| ebi | rs9282858 |
| HLI | rs9282858 |
| Exac | rs9282858 |
| Gnomad | rs9282858 |
| Varsome | rs9282858 |
| LitVar | rs9282858 |
| Map | rs9282858 |
| PheGenI | rs9282858 |
| Biobank | rs9282858 |
| 1000 genomes | rs9282858 |
| hgdp | rs9282858 |
| ensembl | rs9282858 |
| geneview | rs9282858 |
| scholar | rs9282858 |
| rs9282858 | |
| pharmgkb | rs9282858 |
| gwascentral | rs9282858 |
| openSNP | rs9282858 |
| 23andMe | rs9282858 |
| SNPshot | rs9282858 |
| SNPdbe | rs9282858 |
| MSV3d | rs9282858 |
| GWAS Ctlg | rs9282858 |
| GMAF | 0.01791 |
| Max Magnitude | 0 |
"After evaluating over 6,000 cases and 6,000 controls, there is little evidence of a role for the SRD5A2 A49T (i.e. rs9282858) variant in prostate cancer risk."[PMID 18469342
]
[PMID 19914946] Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review
| ClinVar | |
|---|---|
| Risk | rs9282858(A;A) |
| Alt | rs9282858(A;A) |
| Reference | Rs9282858(G;G) |
| Significance | Non-pathogenic |
| Disease | STEROID 5-ALPHA-REDUCTASE POLYMORPHISM not provided |
| Variation | info |
| Gene | SRD5A2 |
| CLNDBN | STEROID 5-ALPHA-REDUCTASE POLYMORPHISM not provided |
| Reversed | 1 |
| HGVS | NC_000002.11:g.31805826C>T |
| CLNSRC | OMIM Allelic Variant |
| CLNACC | RCV000003511.4, RCV000083640.1, |
[PMID 18163429] Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
[PMID 18566991] Joint effects of inflammation and androgen metabolism on prostate cancer severity.
[PMID 26751392] Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
